Anixa Biosciences (ANIX) Share-based Compensation (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Share-based Compensation came in at $637000.0 in Q2 2026, down 33.78% YoY from $962000.0 in Q2 2025, and down 25.84% on a QoQ basis from $859000.0 in Q4 2025.
Anixa Biosciences (ANIX) Share-based Compensation (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Share-based Compensation data on file, last reported at $637000.0 in Q2 2026.
- Quarterly Share-based Compensation fell 33.78% year-over-year to $637000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $3.3 million (down 19.18% YoY) and the FY2025 annual result came in at $3.7 million, down 16.72% from the prior year.
- Share-based Compensation declined to $637000.0 in Q2 2026, from $859000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.1 million in Q1 2022 to a low of $637000.0 in Q2 2026.
- A 5-year average of $1.1 million and a median of $1.1 million in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 144.0% in 2022, down 60.28% in 2022.
- Tracing ANIX's Share-based Compensation over 5 years: stood at $1.1 million in 2022, then gained by 7.93% to $1.2 million in 2023, then retreated by 15.3% to $980000.0 in 2024, then declined by 12.35% to $859000.0 in 2025, then dropped by 25.84% to $637000.0 in 2026.
- The last three Share-based Compensation figures came in at $637000.0 (Q2 2026), $859000.0 (Q4 2025), and $829000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anixa Biosciences | 122.95 Mn | 122.95 Mn | - | 637,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 637,000.00 |
| Apr 30, 2026 | 637,000.00 |
| Oct 31, 2025 | 859,000.00 |
| Oct 31, 2025 | 859,000.00 |
| Jul 31, 2025 | 829,000.00 |
| Jul 31, 2025 | 829,000.00 |
| Apr 30, 2025 | 962,000.00 |
| Apr 30, 2025 | 962,000.00 |
| Jan 31, 2025 | 1.03 Mn |
| Jan 31, 2025 | 1.03 Mn |
| Oct 31, 2024 | 980,000.00 |
| Oct 31, 2024 | 980,000.00 |
| Jul 31, 2024 | 1.09 Mn |
| Jul 31, 2024 | 1.09 Mn |
| Apr 30, 2024 | 1.24 Mn |
| Apr 30, 2024 | 1.24 Mn |
| Jan 31, 2024 | 1.11 Mn |
| Jan 31, 2024 | 1.11 Mn |
| Oct 31, 2023 | 1.16 Mn |
| Oct 31, 2023 | 1.16 Mn |